R1	Subsumes Arg1:T6 Arg2:T7	
*	OR T10 T13 T11 T12
R2	Has_value Arg1:T17 Arg2:T18	
R3	Has_qualifier Arg1:T17 Arg2:T19	
*	OR T15 T14
R4	Has_qualifier Arg1:T16 Arg2:T15	
*	OR T16 T17
*	OR T23 T24 T25
R5	Has_value Arg1:T23 Arg2:T22	
R6	Has_qualifier Arg1:T22 Arg2:T21	
R7	AND Arg1:T28 Arg2:T27	
R8	Has_negation Arg1:T30 Arg2:T31	
R9	AND Arg1:T29 Arg2:T30	
R10	Has_temporal Arg1:T29 Arg2:T32	
*	OR T33 T34
R11	Has_temporal Arg1:T37 Arg2:T38	
R12	Subsumes Arg1:T37 Arg2:T39	
R13	Has_value Arg1:T33 Arg2:T35	
R14	Has_temporal Arg1:T33 Arg2:T36	
*	OR T33 T40 T37
*	OR T43 T42
R15	Has_temporal Arg1:T43 Arg2:T44	
R16	Has_temporal Arg1:T43 Arg2:T46	
R17	Has_temporal Arg1:T48 Arg2:T49	
R18	Has_index Arg1:T49 Arg2:T50	
R19	Has_value Arg1:T52 Arg2:T53	
*	OR T51 T52
*	OR T55 T56
R20	Has_temporal Arg1:T51 Arg2:T55	
*	OR T48 T51
R21	Subsumes Arg1:T60 Arg2:T61	
R23	Subsumes Arg1:T63 Arg2:T64	
R24	Has_value Arg1:T65 Arg2:T63	
R22	Has_value Arg1:T62 Arg2:T60	
*	OR T62 T65
R25	AND Arg1:T62 Arg2:T59	
R26	Subsumes Arg1:T58 Arg2:T62	
*	OR T69 T72 T71 T70 T73
R27	Subsumes Arg1:T68 Arg2:T69	
R28	Has_qualifier Arg1:T77 Arg2:T78	
*	OR T75 T76 T77
R29	Has_qualifier Arg1:T75 Arg2:T79	
R30	Has_multiplier Arg1:T82 Arg2:T83	
R31	Has_multiplier Arg1:T84 Arg2:T85	
*	OR T82 T84
*	OR T88 T89
*	OR T91 T92
R32	Has_qualifier Arg1:T92 Arg2:T93	
R33	Has_qualifier Arg1:T91 Arg2:T93	
T1	Non-query-able 0 153	Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).
T2	Competing_trial 155 328	Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.
T3	Qualifier 360 382	clinically significant
T4	Condition 383 390	disease
T5	Condition 394 402	disorder
T6	Temporal 415 421	recent
T7	Temporal 423 433	< 3 months
T8	Condition 435 455	cardiovascular event
T9	Post-eligibility 330 649	History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study
T10	Condition 674 689	Type 1 diabetes
T11	Condition 691 727	maturity onset diabetes of the young
T12	Condition 729 747	secondary diabetes
T13	Condition 751 769	diabetes insipidus
T14	Qualifier 781 800	rapidly progressing
T15	Qualifier 772 780	Unstable
T16	Condition 801 814	renal disease
T17	Measurement 818 854	estimated Glomerular Filtration Rate
T18	Value 855 866	< 60 mL/min
T19	Qualifier 868 891	Cockcroft-Gault formula
T21	Qualifier 895 917	Clinically significant
T22	Value 918 937	out of range values
T23	Measurement 964 994	alanine aminotransferase (ALT)
T24	Measurement 996 1028	aspartate aminotransferase (AST)
T25	Measurement 1032 1058	alkaline phosphatase (ALP)
T27	Drug 1112 1125	dapagliflozin
T28	Condition 1091 1108	Contraindications
T29	Drug 1164 1182	antidiabetic drugs
T30	Drug 1194 1203	metformin
T31	Negation 1183 1193	other than
T32	Temporal 1204 1238	within 3 months prior to screening
T33	Measurement 1241 1252	Weight gain
T34	Measurement 1241 1247;1256 1260	Weight loss
T35	Value 1261 1267	> 5 kg
T36	Temporal 1268 1288	in the last 3 months
T37	Observation 1298 1314	weight-loss diet
T38	Temporal 1290 1297	ongoing
T39	Observation 1316 1332	hypocaloric diet
T40	Drug 1344 1362	weight loss agents
T42	Observation 1390 1403	alcohol abuse
T43	Observation 1376 1386	drug abuse
T44	Temporal 1404 1425	in the past 12 months
T46	Temporal 1365 1372	History
T47	Post-eligibility 1428 1763	Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.
T48	Procedure 1765 1780	Plasma donation
T49	Temporal 1781 1810	within one month of screening
T50	Reference_point 1801 1810	screening
T51	Procedure 1818 1832	blood donation
T52	Measurement 1833 1843	blood loss
T53	Value 1844 1852	> 500 mL
T55	Temporal 1853 1887	within 3 months prior to screening
T56	Temporal 1891 1907	during the study
T58	Condition 1910 1916	Anemia
T59	Measurement 1928 1943	Hemoglobin (Hb)
T60	Value 1944 1953	< 115 g/L
T61	Value 1955 1961	7.1 mM
T62	Person 1966 1971	women
T63	Value 1976 1985	< 120 g/L
T64	Value 1987 1993	7.5 mM
T65	Person 1998 2001	men
T68	Procedure 2011 2035	anti-coagulant treatment
T69	Drug 2044 2051	heparin
T70	Drug 2053 2061	warfarin
T71	Drug 2063 2082	platelet inhibitors
T72	Drug 2084 2092	thrombin
T73	Drug 2097 2116	factor X inhibitors
T75	Drug 2145 2165	oral glucocorticoids
T76	Drug 2167 2181	anti-estrogens
T77	Drug 2191 2202	medications
T78	Qualifier 2185 2190	other
T79	Qualifier 2221 2259	markedly influence insulin sensitivity
T81	Drug 2269 2283	loop diuretics
T82	Observation 2294 2301	smoking
T83	Multiplier 2286 2293	Regular
T84	Drug 2320 2328	nicotine
T85	Multiplier 2312 2319	regular
T86	Device 2335 2371	Central nervous system aneurysm clip
T87	Device 2373 2400	Implanted neural stimulator
T88	Device 2412 2429	cardiac pacemaker
T89	Device 2433 2446	defibrillator
T90	Device 2448 2464	Cochlear implant
T91	Device 2483 2508	corpora aliena in the eye
T92	Device 2483 2504;2512 2517	corpora aliena in the brain
T93	Qualifier 2466 2482	Metal containing
T94	Non-query-able 2520 2705	Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.
